Search tickers (stock/ETF/mutual fund)...
  • Screener
  • Watchlist
  • Charts
  • Gurus
  • Copilot
    Filings Search  
    Plans   
    Login   
    Register   
    Backtest Portfolio
    Portfolio Optimization
    Asset Correlations
    Efficient Frontier

    ABCL Net Margin

    As of 2025-07-04, the Net Margin of Abcellera Biologics Inc (ABCL) is -564.8%.

    Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.

    ABCL Net Margin - Historical Value
    DateValue
    2024-12-31 -564.8%
    2023-12-31 -385%
    2022-12-31 32.7%
    2021-12-31 40.9%
    2020-12-31 51%
    2019-12-31 -19%
    2018-12-31 3.4%
    -
    -
    -
    ABCL Net Margin - Peers Comparison
    TickerNameValue
    ADPTAdaptive Biotechnologies Corp-89.1%
    ARCH.VArch Biopartners Inc-184.8%
    BASIInotiv Inc-7.7%
    CDXCChromadex Corp8.6%
    CDXSCodexis Inc-110%
    CGENCompugen Ltd-51.1%
    CRLCharles River Laboratories International Inc0.3%
    CSBRChampions Oncology Inc-14.5%
    EVIOEVIO Inc-40.8%
    EVT.DEEvotec SE-24.6%
    ICLRICON PLC9.6%
    IOT.VInnovotech Inc10.2%
    IQVIQVIA Holdings Inc8.9%
    LAXAFLaxai Pharma Ltd1.5%
    MEDPMedpace Holdings Inc19.2%
    MRVIMaravai LifeSciences Holdings Inc-55.9%
    MTSTMetaStat Inc-13652.4%
    PACBPacific Biosciences of California Inc-201.2%
    PBIOPressure Biosciences Inc-1482.2%
    PBSVPharma-Bio Serv Inc-8.2%
    PRAHPRA Health Sciences Inc6.2%
    PSNLPersonalis Inc-96.1%
    QMDTQuick-Med Technologies Inc-76.8%
    RGDXQResponse Genetics Inc-81.9%
    RGENRepligen Corp-4%
    RP.VReplicel Life Sciences Inc-210.1%
    SHCSotera Health Co4%
    SYNHSyneos Health Inc4.9%
    Tickers added to watchlist